Abstract
BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have